Endonovo Therapeutics, Inc.
ENDV
$0.0003
$0.0002200.00%
Recommendation
--
Prev Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
--
P/E (TTM)
--
EPS (TTM)
| 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | |
|---|---|---|---|---|---|
| Net Income | -39.97% | -4.29% | -211.25% | -495.00% | 58.22% |
| Total Depreciation and Amortization | 0.00% | 0.00% | 0.00% | -0.25% | -0.39% |
| Total Amortization of Deferred Charges | -75.34% | -49.31% | -36.87% | -23.23% | -52.96% |
| Total Other Non-Cash Items | 744.89% | 33.05% | 5,714.73% | 14,491.36% | -105.41% |
| Change in Net Operating Assets | -10.93% | 11.54% | 46.83% | 64.36% | 22.37% |
| Cash from Operations | 25.43% | 22.67% | 11.04% | 31.18% | -7.18% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -70.29% | -58.74% | -54.38% | -51.05% | 28.36% |
| Total Debt Repaid | -300.00% | -630.30% | -431.25% | 17.16% | 20.73% |
| Issuance of Common Stock | -- | -- | -- | 12.70% | -100.00% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -29.61% | -18.22% | -14.31% | -44.01% | 8.93% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -233.53% | 479.07% | -88.85% | -218.32% | 440.63% |
